FOLR1 and ovarian carcinoma: In the past 5 years MIRASOL trial stands out as the only study demonstrating a significantly improved response rate (ORR of 42%) for mirvetuximab, a targeted therapy against folate receptor alpha (FRα), in platinum-resistant ovarian cancer patients with high-grade serous histology who have received 1–3 prior lines of treatment, when compared to standard investigator-chosen chemotherapy41.